What is it about?
We explain the background of the nutraceutical palmitoylethanolamide, freely available as the supplement PeaPure, and describe the efficacy and safety in a number of treatment resistant pain patients. PeaPure has also been evaluated related to plasma levels of PEA and after intake PEA levels measured increased at least 2-4 fold.
Featured Image
Why is it important?
Palmitoylethanolamide is a natural compound, endogenous produced in our body, and since 1957 well known for its therapeutic properties. The compound has a demonstrated analgesic effect and can be easily combined with any other analgesic (painkiller).
Perspectives
Meanwhile palmitoylethanolamide is recognized as an analgesic supplement, with an NNT of 1.5 in sciatic pain. This has been published in oktober 2015: https://www.dovepress.com/palmitoylethanolamide-a-neutraceutical-in-nerve-compression-syndromes--peer-reviewed-article-JPR Both clinical as well as preclinical data supports the fact that PEA cal also enhance analgesic effects of classical painkillers, and thus may lead to lower dosages of opiates, pregabalin, etc. This increases compliance and leads to more effect for the patients, with less side effects.
jan keppel hesselink
Institute Neuropathic Pain
Read the Original
This page is a summary of: Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series, Journal of Pain Research, October 2012, Taylor & Francis,
DOI: 10.2147/jpr.s32143.
You can read the full text:
Resources
Biggest website on palmitoylethanolamide in the world
All the scientific papers on palmitoylethanolamide explained and collected in this website: http://palmitoylethanolamide4pain.wordpress.com/
Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series
Video abstract of case series "Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series" to be published in the open access Journal of Pain Research by Jan M Keppel Hesselink and Thecla AM Hekker.
Contributors
The following have contributed to this page







